Takeda Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Takeda Pharmaceutical has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 8.2% per year. Takeda Pharmaceutical's return on equity is 4.2%, and it has net margins of 6.4%.
Key information
10.3%
Earnings growth rate
10.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 8.2% |
| Return on equity | 4.2% |
| Net Margin | 6.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Takeda Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,546,083 | 289,996 | 1,091,066 | 725,957 |
| 30 Jun 24 | 4,413,134 | 149,920 | 1,075,736 | 734,339 |
| 31 Mar 24 | 4,263,762 | 144,067 | 1,053,819 | 728,617 |
| 31 Dec 23 | 4,169,049 | 178,219 | 1,023,306 | 695,012 |
| 30 Sep 23 | 4,154,414 | 191,626 | 1,018,085 | 682,260 |
| 30 Jun 23 | 4,113,631 | 301,398 | 1,013,867 | 652,459 |
| 31 Mar 23 | 4,027,478 | 317,017 | 997,234 | 633,325 |
| 31 Dec 22 | 3,944,611 | 274,525 | 965,908 | 616,009 |
| 30 Sep 22 | 3,749,354 | 213,167 | 934,687 | 569,758 |
| 30 Jun 22 | 3,591,868 | 197,389 | 897,964 | 547,214 |
| 31 Mar 22 | 3,569,006 | 230,059 | 886,327 | 526,087 |
| 31 Dec 21 | 3,465,991 | 438,515 | 897,171 | 495,680 |
| 30 Sep 21 | 3,401,450 | 473,105 | 888,737 | 484,868 |
| 30 Jun 21 | 3,345,565 | 431,178 | 892,983 | 471,424 |
| 31 Mar 21 | 3,197,812 | 376,005 | 875,514 | 455,765 |
| 31 Dec 20 | 3,199,240 | 180,631 | 895,464 | 486,660 |
| 30 Sep 20 | 3,221,804 | 56,051 | 921,830 | 491,903 |
| 30 Jun 20 | 3,243,917 | 119,743 | 928,229 | 486,343 |
| 31 Mar 20 | 3,291,188 | 44,241 | 964,268 | 492,088 |
| 31 Dec 19 | 3,236,697 | 13,275 | 965,530 | 485,736 |
| 30 Sep 19 | 2,876,782 | 83,262 | 867,314 | 440,388 |
| 30 Jun 19 | 2,496,511 | 63,959 | 790,113 | 407,257 |
| 31 Mar 19 | 2,097,224 | 135,192 | 692,728 | 368,257 |
| 31 Dec 18 | 1,780,976 | 110,414 | 608,443 | 317,675 |
| 30 Sep 18 | 1,769,726 | 140,738 | 616,726 | 321,777 |
| 30 Jun 18 | 1,772,125 | 120,339 | 622,667 | 321,719 |
| 31 Mar 18 | 1,770,531 | 186,886 | 628,106 | 325,441 |
| 31 Dec 17 | 1,785,773 | 190,172 | 632,833 | 324,485 |
| 30 Sep 17 | 1,762,667 | 163,457 | 622,191 | 314,755 |
| 30 Jun 17 | 1,746,286 | 160,202 | 616,779 | 310,763 |
| 31 Mar 17 | 1,732,051 | 114,940 | 615,867 | 311,625 |
| 31 Dec 16 | 1,729,967 | 132,194 | 614,187 | 312,149 |
| 30 Sep 16 | 1,754,130 | 150,081 | 627,784 | 332,841 |
| 30 Jun 16 | 1,795,088 | 155,110 | 633,600 | 337,807 |
| 31 Mar 16 | 1,807,378 | 80,166 | 650,336 | 335,704 |
| 31 Dec 15 | 1,831,096 | -111,874 | 650,103 | 386,767 |
| 30 Sep 15 | 1,830,521 | -152,827 | 642,957 | 386,950 |
| 30 Jun 15 | 1,812,971 | -154,591 | 637,726 | 387,932 |
| 31 Mar 15 | 1,777,824 | -145,775 | 612,489 | 367,741 |
| 31 Dec 14 | 1,744,795 | 75,405 | 474,242 | 356,593 |
| 30 Sep 14 | 1,714,694 | 103,390 | 497,474 | 342,907 |
| 30 Jun 14 | 1,692,531 | 110,981 | 522,831 | 339,169 |
| 31 Mar 14 | 1,691,685 | 106,658 | 556,210 | 341,560 |
| 31 Dec 13 | 1,655,033 | 103,330 | 1,036,831 | 10,620 |
Quality Earnings: TKPH.F has a large one-off loss of ¥245.4B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: TKPH.F's current net profit margins (6.4%) are higher than last year (4.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TKPH.F's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: TKPH.F's earnings growth over the past year (51.3%) exceeds its 5-year average (10.3% per year).
Earnings vs Industry: TKPH.F earnings growth over the past year (51.3%) did not outperform the Pharmaceuticals industry 54.6%.
Return on Equity
High ROE: TKPH.F's Return on Equity (4.2%) is considered low.